Acute Repetitive Seizures (ARS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033


 

Seizure clusters, referred to as acute repetitive seizures, are frequent among individuals with epilepsy. These clusters can prove disruptive and burdensome for both patients and their caregivers. The criteria for defining seizure clusters involve two or more seizures within a 24-hour timeframe, which can span hours or even days. The primary risk factor associated with seizure clusters is the presence of intractable epilepsy characterized by a high average seizure frequency. Multifocal epilepsy, symptomatic generalized epilepsy, a previous history of central nervous system infections, and focal cortical dysplasia have all been identified as risk factors for experiencing seizure clusters. Acute repetitive seizures can manifest in various patterns, such as an increased frequency of auras, partial seizures, myoclonic jerks (generalized seizures), or two or more convulsions within a single day. These episodes of acute repetitive seizures can encompass any epileptic seizure and may even affect individuals with epilepsy who are managing their condition with stable anticonvulsant regimens. Many factors believed to trigger acute repetitive seizures overlap with those that can trigger other seizure types, including sleep deprivation, menstruation, infections, and fever. The only FDA-approved rescue medication for seizure clusters is rectal diazepam gel. However, other safe, effective, non-rectal, non-IV benzodiazepines can also treat acute seizures and clusters.

Thelansis’s “Acute Repetitive Seizures (ARS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Acute Repetitive Seizures (ARS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Acute Repetitive Seizures (ARS) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Acute Repetitive Seizures (ARS) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Acute Repetitive Seizures (ARS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Comments

Post a Comment

Popular posts from this blog

Retinitis Pigmentosa (RP) – Market Access and Reimbursement Insights Report – 2025

Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Thelansis’s “Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would improve mar...
Read more

Motor Neurone Disease (MND) – Market Access and Reimbursement Insights Report – 2025

Motor Neurone Disease (MND) Market Access and Reimbursement Insights Thelansis’s “Motor Neurone Disease (MND) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Motor Neurone Disease (MND) Overview Motor neurone disease is a progressive neurological condition in which the nerve cells that control voluntary muscle movement gradually deteriorate. As these neurons are lost, muscles weaken and shrink, leading to increasing difficulty with walking, speaking, swallowing, and eventually breathing. The disease usually begins subtly but advances relentlessly, with most patients facing a shortened life expectancy of only a few ye...
Read more

Uncomplicated Gonorrhea – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2024 To 2034

  Uncomplicated Gonorrhea Market Outlook Thelansis’s “Uncomplicated Gonorrhea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uncomplicated Gonorrhea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Uncomplicated Gonorrhea Overview Uncomplicated gonorrhea is a common sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, a bacterium that primarily affects the mucous membranes of the genital, rectal, and throat areas. The infection spreads through unprotected sexual contact and often presents mild or no symptoms, making early detection challenging. When symptoms do appear, they generally include a burning sensation...
Read more